Latest Intelligence on Therapy Area in South and Central America

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Digene: powerful groups favor HPV test

Published By Datamonitor
27 Jul 2001
CommentWire
CommentWire

Prostate cancer: new study could clear up vitamin E debate

Published By Datamonitor
30 Jul 2001
CommentWire
CommentWire

HIV drugs: patent disputes escalate

Published By Datamonitor
28 Aug 2001
CommentWire
CommentWire

HIV patents: no solution - yet

While the WTO has not yet made a breakthrough on the issue of patent-free HIV drugs for developing economies, something must be done to alleviate the human and economic cost of the HIV epidemic. Western pharma companies will inevitably lose out - the only question is how well their profit maintenance strategies can cushion the blow.

Published By Datamonitor
22 Oct 2002
CommentWire
CommentWire

HIV: US senate may face more pressure

Many patient advocacy groups argue that the US is not contributing sufficiently to HIV prevention and treatment, despite the recent budget approval. Furthermore, most of the major HIV drug manufacturers are either US based or heavily involved in the US - a factor likely to provide additional pressure for increased funding.

Published By Datamonitor
21 May 2003
Expert View
Expert View

Brazilian patent threat poses challenge to big pharma

Relying on its reputation as a world leader in HIV/AIDS drug pricing negotiations, Brazil is threatening to disregard patents unless Abbott Laboratories, Gilead Sciences and Merck & Co. allow it to produce generic versions of their four leading AIDS drugs. Datamonitor's Mar Ferrero investigates the likely ramifications of such a move...

Published By Datamonitor
23 Jun 2005
Expert View
Expert View

Governmental cost-cutting helps generate generics growth

The generic cancer market was worth $1.3 billion in 2004 and is expected to reach $10.9 billion by 2014. This staggering level of growth is attributable to upcoming patent expiries on key products, as well as the imminent introduction of a biogenerics regulatory pathway. However, increasingly cost-conscious governments working to cut healthcare spending will remain generics firms' greatest ally.

Published By Datamonitor
06 Mar 2006
Expert View
Expert View

New advertising code of conduct established in Vioxx withdrawal fallout

Recent high-profile drug withdrawals have resulted in a new code of conduct to govern direct-to-consumer advertising. As more and more drugs are likely to come under regulatory and public scrutiny, the pharmaceutical industry will need to employ effective marketing and education strategies to ensure patient and physician confidence is retained and the impact of drug safety scares is minimized.

Published By Datamonitor
09 Mar 2006
ResearchWire
ResearchWire

Vaccines: sales show global growth

Published By Datamonitor
17 Mar 2006
ResearchWire
ResearchWire

Pulmonary arterial hypertension: market on the pulse of global growth

Published By Datamonitor
17 Mar 2006

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.